Julian Baker’s Immunovant IMVT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$209M Sell
5,435,220
-22,661
-0.4% -$690K 1.05% 16
2026
Q1
$136M Hold
5,457,881
0.78% 18
2025
Q4
$139M Hold
5,457,881
0.81% 18
2025
Q3
$88M Hold
5,457,881
0.64% 20
2025
Q2
$87.3M Hold
5,457,881
0.85% 15
2025
Q1
$93.3M Buy
5,457,881
+3,750,000
+220% +$78.4M 1.03% 14
2024
Q4
$42.3M Buy
1,707,881
+482,471
+39% +$13.7M 0.45% 29
2024
Q3
$34.9M Buy
1,225,410
+760,692
+164% +$22.4M 0.36% 30
2024
Q2
$12.3M Buy
464,718
+39,709
+9% +$1.13M 0.16% 45
2024
Q1
$13.7M Hold
425,009
0.17% 42
2023
Q4
$17.9M Hold
425,009
0.2% 39
2023
Q3
$16.3M Buy
+425,009
New +$9.61M 0.09% 40

Other funds holding IMVT

Julian Baker's IMVT Position: Q2 2026 in Review

Julian Baker reduced its Immunovant (IMVT) stake by 0.42% in Q2 2026, selling an estimated $690K and leaving 5,435,220 shares worth $209M. The position accounts for 1.05% of the portfolio, ranked #16.

Julian Baker first reported a position in IMVT in Q3 2023 and has held it in 12 quarters since. 224 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

  • Julian Baker held 5,435,220 shares of Immunovant worth $209M as of Q2 2026.
  • Julian Baker sold 22,661 Immunovant shares in Q2 2026, an estimated $690K.
  • Immunovant made up 1.05% of Julian Baker's portfolio in Q2 2026, its #16 holding.
  • Julian Baker first reported a position in Immunovant in Q3 2023 and has held it in 12 quarters since.
  • 224 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on Baker Bros. Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.